Invesaro

Stocks Comparison

Charles River Laboratories International vs Iqvia: revenue, profit, margins and growth compared

Charles River Laboratories International brought in $4B of revenue in fiscal 2025, Iqvia $16.3B in fiscal 2025. Revenue changed by -0.9% at Charles River Laboratories International and +5.9% at Iqvia on the year before, so Iqvia grew faster. Charles River Laboratories International kept -3.6% of its revenue as net profit, Iqvia 8.3%. Free cash flow was $518.5M at Charles River Laboratories International and $2.1B at Iqvia.

Open the CRL pageOpen the IQV page

Side by side, latest fiscal year

CRLIQV
Fiscal year endedFY2025 (December 27, 2025)FY2025 (December 31, 2025)
Revenue$4B$16.3B
Revenue growth-0.9%+5.9%
Net income-$144.3M$1.4B
Net margin-3.6%8.3%
Free cash flow$518.5M$2.1B
Free cash flow margin12.9%12.6%
Earnings per share (diluted)-$2.91$7.84
Cash$213.8M$2B
Debt$166K$15.7B
Price to earningsn/a34.5
Market value$14B$44.5B
Dividend yieldn/an/a
Rank by revenue in sector#72 of 523 · Health care#32 of 523 · Health care

Over the years

Revenue
CRL FY2018: $2.3BCRL FY2019: $2.6BCRL FY2020: $2.9BCRL FY2021: $3.5BCRL FY2022: $4BCRL FY2023: $4.1BCRL FY2024: $4BCRL FY2025: $4BIQV FY2018: $10.4BIQV FY2019: $11.1BIQV FY2020: $11.4BIQV FY2021: $13.9BIQV FY2022: $14.4BIQV FY2023: $15BIQV FY2024: $15.4BIQV FY2025: $16.3BFY18FY19FY20FY21FY22FY23FY24FY25
CRL $4BIQV $16.3B
Net income
CRL FY2018: $226.4MCRL FY2019: $252MCRL FY2020: $364.3MCRL FY2021: $391MCRL FY2022: $486.2MCRL FY2023: $474.6MCRL FY2024: $22.2MCRL FY2025: -$144.3MIQV FY2018: $259MIQV FY2019: $191MIQV FY2020: $279MIQV FY2021: $966MIQV FY2022: $1.1BIQV FY2023: $1.4BIQV FY2024: $1.4BIQV FY2025: $1.4BFY18FY19FY20FY21FY22FY23FY24FY25
CRL -$144.3MIQV $1.4B
Net margin
CRL FY2018: 10.0%CRL FY2019: 9.6%CRL FY2020: 12.5%CRL FY2021: 11.0%CRL FY2022: 12.2%CRL FY2023: 11.5%CRL FY2024: 0.5%CRL FY2025: -3.6%IQV FY2018: 2.5%IQV FY2019: 1.7%IQV FY2020: 2.5%IQV FY2021: 7.0%IQV FY2022: 7.6%IQV FY2023: 9.1%IQV FY2024: 8.9%IQV FY2025: 8.3%FY18FY19FY20FY21FY22FY23FY24FY25
CRL -3.6%IQV 8.3%
Revenue growth
CRL FY2019: +15.7%CRL FY2020: +11.5%CRL FY2021: +21.1%CRL FY2022: +12.3%CRL FY2023: +3.9%CRL FY2024: -1.9%CRL FY2025: -0.9%IQV FY2019: +6.5%IQV FY2020: +2.4%IQV FY2021: +22.1%IQV FY2022: +3.9%IQV FY2023: +4.0%IQV FY2024: +2.8%IQV FY2025: +5.9%FY19FY20FY21FY22FY23FY24FY25
CRL -0.9%IQV +5.9%
Free cash flow
CRL FY2018: $301.1MCRL FY2019: $340.4MCRL FY2020: $380MCRL FY2021: $532MCRL FY2022: $294.9MCRL FY2023: $365.4MCRL FY2024: $501.6MCRL FY2025: $518.5MIQV FY2018: $795MIQV FY2019: $835MIQV FY2020: $1.3BIQV FY2021: $2.3BIQV FY2022: $1.6BIQV FY2023: $1.5BIQV FY2024: $2.1BIQV FY2025: $2.1BFY18FY19FY20FY21FY22FY23FY24FY25
CRL $518.5MIQV $2.1B

Fiscal years as each company reports them; the two may end in different months.

Questions about Charles River Laboratories International and Iqvia

Which is bigger by revenue, Charles River Laboratories International or Iqvia?

Iqvia is bigger by revenue: $16.3B in fiscal 2025, against $4B for Charles River Laboratories International in fiscal 2025.

Which keeps more of its revenue as profit, Charles River Laboratories International or Iqvia?

Charles River Laboratories International had a net margin of -3.6% in fiscal 2025; Iqvia had 8.3% in fiscal 2025.

Which grew revenue faster, Charles River Laboratories International or Iqvia?

In their latest fiscal years revenue changed by -0.9% at Charles River Laboratories International and +5.9% at Iqvia.

Where do these numbers come from?

From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.

More comparisons

CRL vs ICLR
CRL vs INCY
CRL vs MEDP
ICLR vs IQV
INCY vs IQV
IQV vs MEDP

Compare more companies